Shares of Smith & Nephew plc (NYSE:SNN) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $41.00.

Several equities research analysts recently weighed in on the company. UBS Group lowered Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Smith & Nephew from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. Finally, Canaccord Genuity restated a “buy” rating and set a $42.00 price target on shares of Smith & Nephew in a research report on Monday, August 6th.

A number of institutional investors have recently added to or reduced their stakes in SNN. Fiduciary Management Inc. WI bought a new stake in Smith & Nephew in the first quarter worth $268,167,000. Summit Trail Advisors LLC boosted its holdings in Smith & Nephew by 187,748.7% in the first quarter. Summit Trail Advisors LLC now owns 1,373,174 shares of the medical equipment provider’s stock worth $1,373,000 after acquiring an additional 1,372,443 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Smith & Nephew by 248.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 678,015 shares of the medical equipment provider’s stock worth $25,446,000 after acquiring an additional 483,215 shares in the last quarter. Dalton Greiner Hartman Maher & Co. boosted its holdings in Smith & Nephew by 180.5% in the second quarter. Dalton Greiner Hartman Maher & Co. now owns 382,612 shares of the medical equipment provider’s stock worth $14,359,000 after acquiring an additional 246,209 shares in the last quarter. Finally, Sensato Investors LLC bought a new stake in Smith & Nephew in the first quarter worth $7,452,000. 8.72% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE SNN traded up $0.22 during mid-day trading on Wednesday, hitting $37.37. 600,382 shares of the stock traded hands, compared to its average volume of 324,571. The company has a quick ratio of 1.05, a current ratio of 2.13 and a debt-to-equity ratio of 0.31. Smith & Nephew has a 52 week low of $33.79 and a 52 week high of $40.43. The firm has a market capitalization of $16.29 billion, a PE ratio of 19.67, a P/E/G ratio of 3.06 and a beta of 0.50.

About Smith & Nephew

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

See Also: What is a Stop Order?

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.